Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Biotech mergers and acquisitions remain strong with billion-dollar-scale deals even in the era of AI unicorns
Currently, the biotechnology industry is consolidating its market position with a quiet yet strong presence, amid the rapid growth and billion-dollar valuations of AI unicorn companies. Over the past two years, mergers and acquisitions in the biotech sector have reached a transaction volume of over $38 billion, and this active trend is expected to continue through 2026.
2024 and 2025 have been recorded as peak periods for biotech M&A activity. It has been confirmed that at least nine American companies in the field completed transactions exceeding $1 billion. The largest deal was Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05 billion.
Although the share of biotechnology in overall recent financing has declined, major acquisition cases continue to advance. Last year, biotech accounted for less than 9% of investments in U.S. startups, hitting a historic low. Initial public offering activity is also subdued.
Currently, the biotech sector shows neither signs of decline nor explosive growth but maintains a stable trend, creating conditions for long-term sustainable development. Against this backdrop, biotech companies are continuously exploring growth opportunities through investment and M&A activities.